Which issue is NOT part of prospective Drug Utilization Review (DUR)?

Prospective Drug Utilization Review (DUR) is a process that evaluates a patient’s medication regimen before a prescription is dispensed to ensure safety and efficacy. This review aims to identify potential problems that could arise with drug therapy.

The issue of monitoring therapeutic appropriateness is an ongoing process and is generally part of concurrent or retrospective DUR, rather than prospective DUR. While therapeutic appropriateness is essential, it typically relates to the ongoing assessment of therapy after the medication has been initiated, rather than evaluating the appropriateness of the therapy before dispensing the drug.

In contrast, drug-diagnosis interactions, incorrect dose or duration, and duplication of therapy are all important components of prospective DUR. Each of these elements revolves around assessing potential issues with a medication prior to its dispensing in order to prevent negative patient outcomes. Therefore, the focus on identifying potential drug-related problems before the therapy starts is key to prospective DUR, making the correct choice that therapeutic appropriateness is not explicitly part of this initial review.